Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical is poised for continued success and growth, with its innovative products, strong revenue growth, and increasing international presence. The launch of its new FDA-cleared body contouring platform, Ayon, is expected to significantly expand its addressable market and contribute to the company's strong financial outlook. With a focus on providing high-quality technology and achieving desired patient outcomes, Apyx is well-positioned to capitalize on the growing demand for energy-based technologies in the aesthetic market. Its updated revenue guidance and ample cash reserves further support the company's positive outlook for the future.

Bears say

Apyx Medical is currently rated as a Buy due to its potential for accelerating growth and positive early momentum with its new product, Ayon. Despite not currently being profitable, the company has made efforts to control costs and has a clear path to sustainable operating profitability. However, risks to the company's growth include competition from other MedTech players, potential regulatory delays, and a highly litigious and regulated industry.

APYX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.